European Medicines Agency - Policies and procedures

What we do
Authorisation of medicines
Who we are
Management Board
Members
Meetings
Executive Director
Deputy Executive Director and support services
Advisory functions
Human Medicines Research and Development
Human Medicines Evaluation
Inspections, Human Medicines Pharmacovigilance and Committees
Veterinary Medicines
Stakeholders and Communication
Information Management
Administration and Corporate Management
How we work
European medicines regulatory network
European experts
Network Strategy to 2020
Information management
EU Telematics
Governance documents
Annual reports and work programmes
Funding
Financial management and budgetary reporting
Policies and procedures
General
Document and information management
Finance
Governance
Infrastructure
Inspection activities
Inspections
Parallel distribution
Meeting management
Meetings management
Scientific and regulatory meetings
Pharmacovigilance
Human
Veterinary
Product authorisation lifecycle
Centralised procedure
Influenza pandemic
Initial evaluation
Post-authorisation
Product development
Maximum residue limits
Orphan medicines
Paediatric medicines
Scientific advice
Support services
Product information
Referrals
Integrated management system
Legal foundation
What we publish
Access to documents
Public hearings
Transparency
Competing interests
Anti-fraud strategy
Handling reports of alleged improprieties
History of EMA
20th anniversary highlights
Careers
Vacancies
Database Administrator
Communication Assistants
Contract Agents for temporary assignments
National experts
Conditions of employment
Application process
Interim placements
Trainee programme
Procurement
Archive
2017
2016
2015
2014
Support to research
Research projects
Benefit-risk methodology
Contact
How to find us
Business hours and holidays
Send a question
Legal
Privacy statement
Complaints
Cookies
Logo and visual identity
About this website
Glossary
FAQs
Translations
UK’s withdrawal from EU

Main navigation

Product authorisation lifecycle